Use of Vitex agnus-castus in patients with menstrual cycle disorders: a single-center retrospective longitudinal cohort study
Authors:
Open Access
- 23 February 2024
- journal article
- research article
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 309 (5) , 2089-2098
Abstract
Purpose: To evaluate clinical characteristics, quality of life (QoL) and effectiveness in patients with menstrual cycle disorders (MCDs) including abnormal uterine bleeding, dysmenorrhea and mastodynia/mastalgia related to premenstrual syndrome taking the Vitex agnus-castus (VAC) products Cyclodynon® or Mastodynon® in a real-world setting. Methods: A single-center retrospective longitudinal cohort study (3 ± 1 months), using data obtained from healthcare data archive and telephone interviews. The main study variables were changes in bleeding, menstrual pain, breast tenderness and patients’ QoL. Results: Data from 1700 women with a mean age of 30.2 years (± 6.3) were analyzed. The most common MCDs were dysmenorrhea (43.8%) and mastodynia/mastalgia (21.1%). Three-month treatment with VAC extract substantially decreased the percentage of patients with irregular cycle (from 9.1% to 0.1%) and breast tenderness (from 39.9% to 0.8%). Improvement in bleeding intensity, frequency and menstrual pain was experienced by 83.4%, 79.2%, and 85.2% of the patients, respectively. When analyzed by disease category, these parameters improved in almost all dysmenorrhea patients, while they improved to a lesser extent in mastodynia/mastalgia patients. QoL improved in all aspects, but was reported by a higher proportion of dysmenorrhea patients compared to mastodynia/mastalgia patients. Treatment was overall well tolerated with a favorable safety profile. Conclusion: These real-world data demonstrate the effectiveness of the VAC-containing products Cyclodynon® and Mastodynon® in the three-month treatment of MCDs, with a pronounced improvement in key disease symptoms and QoL. Intriguingly, while QoL was generally greatly improved, the response to VAC therapy varied depending on the type of underlying MCD.Keywords
Funding Information
- Bionorica SE, Germany
- University of Bern
This publication has 30 references indexed in Scilit:
- Opioidergic mechanisms underlying the actions of Vitex agnus-castus L.Biochemical Pharmacology, 2011
- Dysmenorrhea Prevalence among Adolescents in Eastern Turkey: Its Effects on School Performance and Relationships with Family and FriendsJournal of Pediatric and Adolescent Gynecology, 2010
- Primary DysmenorrheaObstetrics & Gynecology, 2006
- Vitex agnus castusDrug Safety, 2005
- Fructus agni casti and bromocriptine for treatment of hyperprolactinemia and mastalgiaInternational Journal of Gynecology & Obstetrics, 2004
- Chaste tree (Vitex agnus-castus) – Pharmacology and clinical indicationsPhytomedicine, 2003
- Can it work? Does it work? Is it worth it?BMJ, 1999
- Randomized controlled trial of the management of premenstrual syndrome and premenstrual mastalgia using luteal phase–only danazolAmerican Journal of Obstetrics and Gynecology, 1999
- In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus castus: direct evidence for a dopaminergic principle by the dopamine receptor assayExperimental and Clinical Endocrinology & Diabetes, 1994
- Double-blind trial of promegestone (R 5020) and lynestrenol in the treatment of benign breast diseaseEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 1992